Clinical trial · Interventional
Telemedicine in the Management of Pain in Patients With Advanced or Metastatic Pancreatic Cancer
NCT04667403CI-TRIAL-00058129PANTELOunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Adenocarcinoma of the pancreas is a major public health issue because of its disastrous prognosis. The symptomatology of locally advanced or metastatic forms, particularly painful, is often major and difficult to balance, impacting both the quality of life of patients (and those around them) and the course of treatment (chemotherapy). The objective of this study is to evaluate the interest and feasibility of telemedicine in the management of pain in patients undergoing treatment for advanced or metastatic pancreatic cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
| Pain | — | UNRESOLVED | — |
| Pancreatic Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Telemedicine | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Telemedicine
- description
- Pain is monitored, from the patient's home, using a computer application accessible from a smartphone or a computer with internet access. This application will allow the patient to describe his or her pain by means of a self-questionnaire. Healthcare professionals (nurse coordinator, pain specialist and oncologist) will thus be able to remotely interpret the data collected, enabling them to provide patients with a rapid response to adapt their pain treatment without the patient having to travel to the establishment.
- interventionNames
- Other: Telemedicine
Primary outcomes (1)
- measure
- Satisfaction of patients with advanced or metastatic pancreatic cancer of the impact of telemedicine in the management of their pain.
- timeFrame
- at one month, 3 months and 6 months post-inclusion
- description
- Satisfaction is measured using the Patient Global Clinical Impression of Change (P-GIC) questionnaire. The questionnaire consists of a single question posed to the patient via the application asking the patient what impact he or she believes telemedicine has had on the overall management of his or her pain. The patient has the following 8 propositions among which he must indicate the one that best corresponds to the perceived change: Don't know, Very strongly positive, Strongly positive, Slightly positive, No change, Slightly negative, Strongly negative, Very strongly negative.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient ≥ 18 years old ; * Patient with histologically or cytologically proven locally advanced and/or metastatic adenocarcinoma of the pancreas; * Patient undergoing or failing medical treatment and comfort care only; * Patient with EVA ≥ 4 and/or requiring analgesics level 3; * Performans Status (ECOG) \< 3 ; * Informing the patient and obtaining free, informed and written consent signed by the patient and the investigator; * Patient affiliated or beneficiary of the social security system Exclusion Criteria: * Patient does not have a smartphone, tablet or computer; * Patient with no personal internet access at home (WIFI, wired), or via his smartphone; * Patient does not feel able to fill out an electronic questionnaire; * Patient cannot read or write French; * Patient does not speak and understand French; * Persons deprived of liberty or under guardianship or trusteeship ; * Dementia, mental alteration or psychiatric pathology that could compromise the patient's informed consent and/or compliance with the protocol and follow-up of the trial ; * Inability to submit to trial protocol follow-up for geographical, social, or other reasons ; * Patient participating in another interventional study evaluating treatment and pain management.
References
Publications (0)
Data not yet available
No reference posted for this study.